Inhibition of protein kinase C-driven nuclear factor-κB activation: Synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules

Journal of Medicinal Chemistry

Volumn 53, Issue 12, 2010, Pages 4793-4797

  Peddibhotla, Satyamaheshwar ^a   Shi, Ranxin ^a   Khan, Pasha ^a   Smith, Layton H ^a   Mangravita Novo, Arianna ^a   Vicchiarelli, Michael ^a   Su, Ying ^a   Okolotowicz, Karl J ^b   Cashman, John R ^b   Reed, John C ^a   Roth, Gregory P ^a  

^a BURNHAM INSTITUTE   (United States)

^b HUMAN BIOMOLECULAR RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,5 DI TERT BUTYL 4 HYDROXYPHENYL) 2 (2 ((3 HYDROXYPROPYL)AMINO) 5,6 DIMETHYL 1H BENZO[D]IMIDAZOL 1 YL)ETHANONE; 2 AMINOALKYLBENZIMIDAZOLE DERIVATIVE; 2 AMINOBENZIMIDAZOLE; 2 BENZIMIDAZOLONE DERIVATIVE; 2 BROMO 5,6 DIMETHYLBENZIMIDAZOLE; 2 BROMOBENZIMIDAZOLE; 2H BENZIMIDAZOLE; BENZIMIDAZOLE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE C; UNCLASSIFIED DRUG;

ARTICLE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG METABOLISM; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN TARGETING; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZIMIDAZOLES; CELL LINE; CELL MEMBRANE PERMEABILITY; GENES, REPORTER; HEPATOCYTES; HUMANS; HYDROPHOBICITY; INTERLEUKIN-2; INTERLEUKIN-8; MALE; MICE; MICROSOMES, LIVER; NF-KAPPA B; PROTEIN KINASE C; RECEPTORS, ANTIGEN, B-CELL; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77953790002     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1000248     Document Type: Article

References (20)

1. Tracey, K. J.; Cerami, A. Tumor necrosis factor, other cytokines and disease Annu. Rev. Cell Biol. 1993, 9, 317-343
2. Baud, V.; Karin, M. Is NF-κB a good target for cancer therapy? Hopes and pitfalls Nat. Rev. Drug Discovery 2009, 8, 33-40
3. Bonizzi, G.; Karin, M. The two NF-κB activation pathways and their role in innate and adaptive immunity Trends Immunol. 2004, 25, 280-288
4. Gilmore, T. D. Introduction to NF-kB: players, pathways, perspectives Oncogene 2006, 25, 6680-6684
5. Karin, M.; Delhase, M. The I-kappa B kinase (IKK) and NF-kappa B: key elements of pro-inflammatory signalling Semin. Immunol. 2000, 12, 85-98
6. Schulze-Luehrmann, J.; Ghosh, S. Antigen-receptor signaling to nuclear factor kappa B Immunity 2006, 25, 701-715
7. Hayden, M. S.; West, A. P.; Ghosh, S. NF-kappaB and the immune response Oncogene 2006, 25, 6758-6780
8. Thome, M. CARMA1, BCL-10 and MALT1 in lymphocyte development and activation Nat. Rev. Immunol. 2004, 4, 348-359
9. Gilmore, T. D.; Herscovitch, M. Inhibitors of NF-kappaB signaling: 785 and counting Oncogene 2006, 25, 6887-6899
10. Kanters, E.; Pasparakis, M.; Gijbels, M. J. J.; Vergouwe, M. N.; Partouns-Hendriks, I.; Fijneman, R. J. A.; Clausen, B. E.; Förster, I.; Kockx, M. M.; Rajewsky, K.; Kraal, G.; Hofker, M. H.; de Winther, M. P. J. Inhibition of NF-κB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice J. Clin. Invest. 2003, 112, 1176-1185
11. NIH Molecular Libraries Small Molecule Repository; http://mlsmr.glpg.com/ MLSMR-HomePage. Accessed May 6, 2010.
12. For assay details see Supporting Information and PubChem link to AIDs 465 and 1384 http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=465; http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid= 1384). Accessed May 6, 2010.
13. Shi, R.; Re, D.; Dudl, E.; Cuddy, M.; Okolotowicz, K. J.; Dahl, R.; Su, Y.; Hurder, A.; Kitada, S.; Peddibhotla, S.; Roth, G. P.; Smith, L. H.; Kipps, T. J.; Cosford, N.; Cashman, J.; Reed, J. C. Chemical biology strategy reveals pathway-selective inhibitor of NF-κB activation induced by protein kinase C and antigen receptors ACS Chem. Biol. 2010, 5, 287-299
14. Riccardo, A.; Lucarini, M.; Mugnaini, V.; Pedulli, G. F. Antioxidant activity of o -bisphenols: the role of intramolecular hydrogen bonding J. Org. Chem. 2003, 68, 5198-5204
15. Van Allan, J. A.; Deacon, B. D. 2-Mercaptobenzimidazole. In Organic Syntheses; Wiley & Sons: New York, 1963; Collect. Vol. IV, pp 569 - 570.
16. Nadipuram, A. K.; David, W. M.; Kumar, D.; Kerwin, S. M. Synthesis and thermolysis of heterocyclic 3-aza-3-ene-1,5-diynes Org. Lett. 2002, 4, 4543-4546
17. Ellingboe, J. W.; Spinelli, W.; Winkley, M. W.; Nguyen, T. T.; Parsons, R. W.; Moubarak, I. F.; Kitzen, J. M.; Von Engen, D.; Bagli, J. F. Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides J. Med. Chem. 1992, 35, 705-716
18. Pagano, M. A.; Andrzejewska, M.; Ruzzene, M.; Sarno, S.; Cesaro, L.; Bain, J.; Elliott, M.; Meggio, F.; Kazimierczuk, Z.; Pinna, L. A. Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole J. Med. Chem. 2004, 47, 6239-6247
19. Anisimova, V. A.; Osipova, M. M.; Galenko-Yaroshevskii, A. P.; Ponomarev, V. V.; Popkov, V. L.; Prikhodko, A. K.; Kade, E. A.; Spasov, A. A. Synthesis and local anesthetic activity of 1,2-disubstituted imidazo[1,2- a ]benzimidazoles Pharm. Chem. J. (Translation of Khim.-Farm. Zh.) 2002, 36, 418-422
20. i determinations, receptor binding profiles, agonist and/or antagonist functional data, hERG data, MDR1 data, etc. was generously provided by the National Institute of Mental Healths Psychoactive Drug Screening Program, Contract no. NO1MH32004 (NIMH PDSP). The NIMH PDSP is directed by Dr. Bryan L. Roth M.D., Ph.D. at the University of North Carolina at Chapel Hill and Project Officer Jamie Driscoll at NIMH, Bethesda MD.